These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24800945)

  • 41. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.
    Ishida S; Lee J; Thiele DJ; Herskowitz I
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14298-302. PubMed ID: 12370430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
    Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
    Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
    Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
    Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance.
    Stefan SM; Jansson PJ; Kalinowski DS; Anjum R; Dharmasivam M; Richardson DR
    Future Med Chem; 2020 Mar; 12(6):473-477. PubMed ID: 32098489
    [No Abstract]   [Full Text] [Related]  

  • 46. Downregulation of hepatic multi-drug resistance protein 1 (MDR1) after copper exposure.
    Groba SR; Guttmann S; Niemietz C; Bernick F; Sauer V; Hachmöller O; Karst U; Zischka H; Zibert A; Schmidt HH
    Metallomics; 2017 Sep; 9(9):1279-1287. PubMed ID: 28805879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic internalization and recycling of a metal ion transporter: Cu homeostasis and CTR1, the human Cu⁺ uptake system.
    Clifford RJ; Maryon EB; Kaplan JH
    J Cell Sci; 2016 Apr; 129(8):1711-21. PubMed ID: 26945057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Involvement of CTR1 and ATP7A in lead (Pb)-induced copper (Cu) accumulation in choroidal epithelial cells.
    Zheng G; Zhang J; Xu Y; Shen X; Song H; Jing J; Luo W; Zheng W; Chen J
    Toxicol Lett; 2014 Feb; 225(1):110-8. PubMed ID: 24316150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein.
    Teng YN; Wang CCN; Liao WC; Lan YH; Hung CC
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936160
    [No Abstract]   [Full Text] [Related]  

  • 50. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
    Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
    PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
    Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
    Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
    Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
    Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
    BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Derivation of a System-Independent
    Chaudhry A; Chung G; Lynn A; Yalvigi A; Brown C; Ellens H; O'Connor M; Lee C; Bentz J
    Drug Metab Dispos; 2018 Mar; 46(3):279-290. PubMed ID: 29317410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
    Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
    Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.